- Home
- AEON vs RVPH Comparison
AEON vs RVPH Comparison
Compare AEON & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- RVPH
- Stock Information
- Founded
- AEON N/A
- RVPH 2006
- Country
- AEON United States
- RVPH United States
- Employees
- AEON N/A
- RVPH N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- RVPH Health Care
- Exchange
- AEON Nasdaq
- RVPH Nasdaq
- Market Cap
- AEON 36.4M
- RVPH 33.4M
- IPO Year
- AEON N/A
- RVPH N/A
- Fundamental
- Price
- AEON $0.61
- RVPH $1.13
- Analyst Decision
- AEON Strong Buy
- RVPH Strong Buy
- Analyst Count
- AEON 1
- RVPH 4
- Target Price
- AEON $5.00
- RVPH $15.33
- AVG Volume (30 Days)
- AEON 106.3K
- RVPH 697.8K
- Earning Date
- AEON 11-13-2024
- RVPH 11-26-2024
- Dividend Yield
- AEON N/A
- RVPH N/A
- EPS Growth
- AEON N/A
- RVPH N/A
- EPS
- AEON N/A
- RVPH N/A
- Revenue
- AEON N/A
- RVPH N/A
- Revenue This Year
- AEON N/A
- RVPH N/A
- Revenue Next Year
- AEON N/A
- RVPH N/A
- P/E Ratio
- AEON N/A
- RVPH N/A
- Revenue Growth
- AEON N/A
- RVPH N/A
- 52 Week Low
- AEON $0.60
- RVPH $0.60
- 52 Week High
- AEON $17.17
- RVPH $5.67
- Technical
- Relative Strength Index (RSI)
- AEON 28.55
- RVPH 49.00
- Support Level
- AEON $0.60
- RVPH $0.88
- Resistance Level
- AEON $0.88
- RVPH $1.45
- Average True Range (ATR)
- AEON 0.07
- RVPH 0.14
- MACD
- AEON -0.03
- RVPH 0.02
- Stochastic Oscillator
- AEON 2.62
- RVPH 42.98
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.